FORM 10-QSB

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

(Mark One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

     For the Quarterly period ended March 31, 1999

OR

[ ]  TRANSITION REPORT PURUSANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

Commission file number 0-14306

                     INTERCELL CORPORATION
                     ---------------------
(Exact name of small business issuer as specified in its charter)

     Colorado                              84-0928627
     --------                              ----------
(State or other jurisdiction of                    (I.R.S. employer
 incorporation or organization)                 identification number)

          370 17th Street, Suite 3580
            Denver, Colorado 80202
(Address of principal executive offices) (Zip Code)

Issuer's telephone number, including area code:  (303) 592-1010


                       Not applicable
(Former name, former address or former fiscal year, if changed since last
report)


Indicate by check mark whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.   Yes   X    No
                                          ---       ---


As of July 30, 1999 there were 55,544,743 shares of the registrant's sole class
of common shares outstanding.


Transitional Small Business Disclosure Format          Yes  X      No
                                                           ---        ---


<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
                                      INDEX


PART I - FINANCIAL INFORMATION


ITEM 1.  FINANCIAL STATEMENTS                                            PAGE
                                                                         ----

    Condensed Consolidated Balance Sheet
       March 31, 1999                                                      1

    Condensed Consolidated Statements of Operations
       For the Three and Six Months Ended March 31, 1999 and 1998          2

    Condensed Consolidated Statement of Changes in Stockholders' Equity
       For the Six Months Ended March 31, 1999                             3

    Condensed Consolidated Statements of Cash Flows
       For the Six Months Ended March 31, 1999 and 1998                    4

    Notes to Condensed Consolidated Financial Statements
       March 31, 1999                                                      6


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
         CONDITION AND RESULTS OF OPERATIONS                              11


PART II - OTHER INFORMATION                                               13


ITEM 2.  CHANGES IN SECURITIES                                            14

ITEM 6.  EXHIBITS                                                         14


    SIGNATURES




























<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
                      Condensed Consolidated Balance Sheet
                                   (Unaudited)
                                 March 31, 1999
<TABLE>
<CAPTION>
Assets
-------
<S>                                                            <C>
Current assets:
  Cash and cash equivalents                                    $     26,000
  Restricted cash                                                    16,000
  Note receivable, current portion                                   12,000
                                                                -----------
    Total current assets                                             54,000

Note receivable, less current portion                                36,000
Investment in land held for sale                                    500,000
Other assets                                                         17,000
                                                                -----------

       Total assets                                            $    607,000
                                                                ===========

Liabilities and Stockholders' Deficit
--------------------------------------

Current liabilities:
  Notes payable to related parties                             $    160,000
  Accounts payable and accrued liabilities                          951,000
  Convertible debentures                                            826,000
  Liabilities of discontinued operations                          3,347,000
                                                                -----------
    Total current liabilities                                     5,284,000
                                                                -----------

Contingencies

Stockholders' deficit:
  Convertible preferred stock; 10,000,000 shares authorized:
    Series C; 143 shares issued and outstanding
     (liquidation preference of $1,608,750)                       1,381,000
    Series D; 1,080 shares issued and outstanding
     (liquidation preference of $2,700,000)                       2,491,000
  Warrants to acquire common stock                                3,075,000
  Common stock; no par value; 100,000,000 shares authorized
    41,319,591 shares issued and outstanding                     21,486,000
  Additional paid-in capital                                      4,891,000
  Accumulated deficit                                           (38,001,000)
                                                                -----------
      Total stockholders' deficit                               ( 4,677,000)
                                                                -----------

        Total liabilities and stockholders' deficit            $    607,000
                                                                ===========

<FN>

See accompanying notes to consolidated financial statements.
</TABLE>





                                        1

<PAGE>


                     INTERCELL CORPORATION AND SUBSIDIARIES
                 Condensed Consolidated Statements of Operations
                                   (Unaudited)
<TABLE>
<CAPTION>
                                              Three Months Ended                 Six Months Ended
                                                   March 31,                         March 31,
                                           ------------------------             ------------------
                                           1999                1998             1999          1998
                                   --------------------  -----------------  ------------  ------------
<S>                                <C>                   <C>                <C>           <C>
General and administrative
  expense                          $      311,000          1,123,000          728,000       2,604,000
                                      ------------       ------------      ----------     ------------

Loss from operations                  (   311,000)       ( 1,123,000)      (  728,000)    ( 2,604,000)
                                      ------------       ------------      -----------    ------------

Interest income                               -                1,000              -           116,000
Interest expense                      (    21,000)       (   298,000)     (    41,000)    (   303,000)
                                      ------------       ------------     ------------    ------------
                                      (    21,000)       (   297,000)     (    41,000)    (   187,000)
                                      ------------       ------------     ------------    ------------

Loss from continuing operations       (   332,000)       ( 1,420,000)     (   769,000)    ( 2,791,000)
                                      ------------       ------------     ------------    ------------

Discontinued operations:
  Loss from operations to
   be disposed of                             -          ( 1,063,000)     (    67,000)    ( 2,691,000)
  Loss on sale of subsidiary                  -          (   350,000)             -       (   350,000)
                                      ------------       ------------     ------------    ------------

Loss from discontinued operations             -          ( 1,413,000)     (    67,000)    ( 3,041,000)
                                      ------------       ------------     ------------    ------------

Net loss                              (   332,000)       ( 2,833,000)     (   836,000)    ( 5,832,000)

Deemed dividend on Series C and D
  preferred stock relating to
  in-the-money conversion terms       (    15,000)       (    30,000)     (    29,000)    (    30,000)
Accrued dividends on Series D
  preferred stock                     (    38,000)       (    37,000)     (    75,000)    (    37,000)
Accretion on Series B and C
  preferred stock                     (    29,000)       (    29,000)     (    58,000)    (    64,000)
                                      ------------       ------------     ------------    ------------

Net loss applicable to common
  stockholders                     $  (   414,000)       ( 2,929,000)     (   998,000)    ( 5,963,000)
                                      ============       ============     ============    ============

Net loss per share, basic and
   diluted, applicable
   to common stockholders:
  Loss from continuing operations  $  (      0.01)       (      0.05)     (      0.03)    (      0.10)
  Loss from discontinued
   operations                         (      0.00)       (      0.04)     (      0.00)    (      0.10)
                                      ------------       ------------     ------------    ------------

  Net loss                         $  (      0.01)       (      0.09)     (      0.03)    (      0.20)
                                      ============       ============     ============    ============

Weighted average number of common
  shares outstanding                   39,500,246         32,061,656       38,514,887      30,222,670
                                       ==========         ==========       ==========     ===========
<FN>
See accompanying notes to consolidated financial statements.
</TABLE>
                                        2
<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
  Condensed Consolidated Statement of Changes in Stockholders' Equity(Deficit)
                                   (Unaudited)
                         Six Months Ended March 31, 1999
<TABLE>
<CAPTION>
                                     Convertible
                                   Preferred Stock        Warrants to        Common Stock
                                 --------------------       Acquire     ------------------------
                                 Shares        Amount     Common Stock    Shares       Amount
                                 ------     -----------   ------------  ----------  ------------
<S>                              <C>      <C>              <C>          <C>         <C>
Balances, October 1, 1998         1,227   $  3,749,000     3,075,000    36,670,634  $ 21,329,000

Common stock issued for
  settlements                                                            2,718,763       118,000
Conversion of Series C
  Preferred Stock                (    4)     (  39,000)                  1,930,194        39,000
Common stock issued
  by subsidiary
Accretion on preferred stock                    58,000
Amortization of deemed dividend                 29,000
Accrual of preferred stock
  dividend                                      75,000
Net loss
                                 ------    -----------    ----------   -----------   -----------
Balance as of March 31, 1999      1,223   $  3,872,000     3,075,000    41,319,591  $ 21,486,000
                                 ======    ===========    ==========   ===========   ===========

                                                                 Total
                                   Additional                 Stockholders'
                                    Paid-in     Accumulated      Equity
                                    Capital       Deficit       (Deficit)
                                  -----------   -----------   -------------
<S>                                <C>          <C>           <C>
Balances, October 1, 1998          4,098,000    (37,003,000)  (4,752,000)

Common stock issued for
  settlements                                                    118,000
Conversion of Series C
  Preferred Stock
Common stock issued
  by subsidiary                      793,000
Accretion on preferred stock.                   (    58,000)
Amortization of deemed dividend                 (    29,000)
Accrual of preferred stock
  dividend                                      (    75,000)
Net loss                                        (   836,000)  (  836,000)
                                  ----------     ----------    ---------
Balance as of March 31, 1999       4,891,000    (38,001,000)  (4,677,000)
                                  ==========     ==========    =========

</TABLE>












                                        3

<PAGE>


                     INTERCELL CORPORATION AND SUBSIDIARIES
                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                    Six Months Ended
                                                                       March 31,
                                                               -------------------------
                                                                 1999             1998
                                                               --------         --------
<S>                                                         <C>               <C>
Cash flows from operating activities:
 Net loss                                                   $  (   836,000)    ( 5,832,000)
 Less loss from discontinued operations                             67,000       3,141,000
                                                             --------------    ------------
   Loss from continuing operations                             (   769,000)    ( 2,691,000)
 Adjustments to reconcile net loss to net cash used in
  in operating activities:
  Amortization of intangible assets                                    -             1,000
  Loss on abandonment/sale of property, plant, and equipment           -           900,000
  Common stock and warrants issued for
    interest/services/settlements                                  118,000         252,000
  Common stock of subsidiary issued for services                       -           472,000
  Changes in operating assets and liabilities:
   (Increase) decrease in prepaid expenses
     and other current assets                                          -       (   599,000)
   Increase (decrease) in accounts payable
     and accrued liabilities                                       138,000          52,000
   Increase in payables to related parties                                             -
   Other                                                             3,000             -
                                                             --------------    ------------
    Net cash used in continuing operations                     (   510,000)    ( 1,613,000)
                                                             --------------    ------------
    Net cash (used in) provided by discontinued operations             -       ( 1,009,000)
                                                             --------------    ------------

Cash flows from investing activities:
 Other assets                                                       11,000             -
 Proceeds from disposition of business and sales of
   property and equipment                                              -         1,500,000
                                                             --------------    ------------
    Net cash provided by investing activities                       11,000       1,500,000
                                                             --------------    ------------

Cash flows from financing activities:
 Proceeds from sale of stock by subsidiary                         200,000            -
 Proceeds from notes payable                                       146,000       1,500,000
 Repayments of notes payable                                      ( 72,000)       (180,000)
                                                             --------------    ------------
    Net cash provided by financing activities                      274,000       1,320,000
                                                             --------------    ------------

Net increase (decrease) in cash and cash equivalents           (   225,000)        198,000
Cash and cash equivalents beginning of period                      251,000          11,000
                                                             --------------    ------------
Cash and cash equivalents end of period                     $       26,000         209,000
                                                             ==============    ============

Supplemental disclosure of cash flow information:
 Cash paid for interest                                     $        4,000          81,000
                                                             ==============    ============

</TABLE>



                                        4

<PAGE>


                     INTERCELL CORPORATION AND SUBSIDIARIES
                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)


Supplemental disclosure of noncash investing and financing activities:
                                                             1999        1998
                                                             ----        ----
Additional paid-in capital from conversion
 feature of debentures                                   $     -      $ 225,000
Conversion of Series B preferred stock to common stock      39,000          -
Accretion on preferred stock                                58,000       64,000
Amortization of deemed dividend on preferred stock          29,000       30,000
Accrual of preferred stock dividend                         75,000       37,000

See accompanying notes to consolidated financial statements.


















































                                        5
<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                         SIX MONTHS ENDED MARCH 31, 1999


1.  PRESENTATION OF INTERIM INFORMATION

The accompanying consolidated financial statements include the accounts of
Intercell Corporation and its wholly-owned subsidiaries (the "Company").  All
inter-company transactions have been eliminated.

In the opinion of the management of the Company, the accompanying unaudited
consolidated financial statements include all material adjustments, including
all normal recurring adjustments, considered necessary to present fairly the
financial position of and operating results for the periods presented.  The
financial statements and notes are presented as permitted by Form 10-QSB, and do
not contain certain information included in the Company's last Annual Report on
Form 10-KSB for the fiscal year ended September 30, 1998.  It is the Company's
opinion that when the interim statements are read in conjunction with the
September 30, 1998 Annual Report on Form 10-KSB, the disclosures are adequate to
make the information presented not misleading.  Interim results are not
necessarily indicative of results for a full year or any future period.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern.  The Company has incurred
significant operating losses, and has a working capital deficiency and a
stockholders' deficit at March 31, 1999.  These conditions raise substantial
doubt about its ability to continue as a going concern.  The financial
statements do not include any adjustments to reflect the possible future effects
on the recoverability and classification of assets or amounts and
classifications of liabilities that might result from the outcome of this
uncertainty.

The Company has formulated plans and strategies to address the Company's
financial condition and increase profitability, including the following:

a.  Through 1998, the Company discontinued, sold, and/or abandoned certain of
its operations, which management anticipates will eliminate significant
operating and overhead expenses, and which have contributed to the Company's
losses in the past.

b.  The Company completed the acquisition of Nanopierce in 1998, which the
Company intends to market its PI Technology, primarily through the development
of strategic relationships with established leaders in the technology industry,
the licensing of the PI Technology and/or the sale of products incorporating the
PI Technology.

c.  The Company is continuing efforts to seek and obtain debt and/or equity
financing to further support its operating needs.


2.  USE OF ESTIMATES

The preparation of consolidated financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and reported amounts of revenues and expenses during the
reporting periods.  Actual results could differ from those estimates.


3.  RECLASSIFICATIONS

Certain amounts in the 1998 financial statements have been reclassified to
conform with the 1999 presentation.

                                        6
<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                         SIX MONTHS ENDED MARCH 31, 1999


4.  NET LOSS PER SHARE

Net loss per share of common stock is computed based on the weighted average
number of common shares outstanding during the year.  Stock options, warrants
and convertible preferred stock are not considered in the calculation as the
impact of the potential common shares would be to decrease loss per share.
Therefore, diluted loss per share is equivalent to basic loss per share.

The Company adopted Statement of Financial Accounting Standards (SFAS) No. 128
Earnings Per Share during 1998.  This statement requires dual presentation of
basic and diluted earnings per share (EPS) with a reconciliation of the
numerator and denominator of the basic EPS computation to the numerator and
denominator of the diluted EPS computation.  Basic EPS excludes dilution.
Diluted EPS reflects the potential dilution that could occur if securities or
other contracts to issue common stock were exercised or converted into common
stock or resulted in the issuance of common stock that then shared in the
earnings of the entity.


5.  RECENT ACCOUNTING PRONOUNCEMENTS

In 1997, the FASB, issued SFAS No. 131, Disclosures about Segments of an
Enterprise and Related Financial Information, and in February 1998, the FASB
issued SFAS No. 132, Employers' Disclosure about Pensions and Other Post
Retirement Benefits.  Both of these statements are effective for fiscal years
beginning after December 31, 1997, require disclosure only and therefore will
not impact the Company's financial statements.

In June 1998, the FASB issued SFAS No. 133, Accounting for Derivative
Instruments and Hedging Activities.  This statement, as amended by SFAS No. 137,
is effective for fiscal years beginning after June 15, 2000.  Currently, the
Company does not have any derivative financial instruments and does not
participate in hedging activities.  Therefore, management believes that SFAS No.
133 will not have an impact on its financial statements.


6.  RISK CONSIDERATIONS

BUSINESS RISK

The Company is subject to risks and uncertainties common to technology-based
companies, including rapid technological change, dependence on principal
products and third party technology, new product introductions and other
activities of competitors, dependence on key personnel, and limited operating
history.

YEAR 2000 CONVERSION

The Company recognizes the need to ensure its operations will not be adversely
impacted by Year 2000 software failures.  Software failures due to processing
errors potentially arising from calculations using the Year 2000 date are a
known risk.  The Company is addressing this risk to the availability and
integrity of financial systems and the reliability of the operational systems.
The Company has established processes for evaluating and managing the risks and
costs associated with this problem.  Management believes the total cost of
compliance, and its effect on the Company's future results of operations will be
insignificant.


                                        7

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                         SIX MONTHS ENDED MARCH 31, 1999


7.  COMPREHENSIVE INCOME

The Company has adopted Statement of Financial Accounting Standards No. 130,
Reporting Comprehensive Income.  This standard establishes requirements for
disclosure of comprehensive income consisting of certain items previously not
included in the statements of operations including unrealized gains and losses
among others.  For the six months ended March 31, 1999 and 1998, the Company has
no items of comprehensive income.


8.  DISCONTINUED OPERATIONS

The Company sold its wholly-owned subsidiary, CTL, on February 6, 1998; the
Company effectively terminated the non-PI Technology related operations and
activities of PI Corp. in September 1997 and transferred the PI Technology to
Nanopierce in February, 1998; the Company sold CMI and IWC in July 1997, and in
June 1998, the Company discontinued all operations of Sigma.  Sigma filed for
voluntary liquidation under Chapter 7 of the U.S. Bankruptcy Code on December
30, 1998.  The summarized results of discontinued operations are as follows:

1999                CTL       CMI       IWC       SIGMA      PI CORP    TOTAL
----              ------    ------    -------    -------     --------   -----

Net sales     $       -         -         -           -         -           -
Loss from
 Operations   $       -         -         -    (   67,000)      -     (  67,000)
Gain (loss)
 on Disposal  $       -         -         -           -         -           -

1998                CTL       CMI       IWC       SIGMA      PI CORP    TOTAL
----              ------    ------    -------    -------     -------    -----

Net sales     $ 1,710,000   814,000       -       354,000       -     2,878,000
Income
 (loss) from
 operations   $(  215,000) (  6,000) (838,000) (1,530,000) (102,000) (2,691,000)
Gain (loss)
 on disposal  $(  350,000)      -         -           -         -    (  350,000)

Liabilities of discontinued operations at March 31, 1999, consist of Sigma
liabilities as follows:

Accounts payable and accrued liabilities                 $   986,000
Notes payable                                              2,240,000
Other liabilities                                            121,000
                                                          ----------
                                                         $ 3,347,000
                                                          ==========

Notes payable of discontinued operations primarily consist of $1,700,000, 10%,
unsecured notes payable issued in a 1997 private placement, originally due in
October 1998.







                                        8

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                         SIX MONTHS ENDED MARCH 31, 1999


9.  ACQUISITION OF NANOPIERCE TECHNOLOGIES, INC.

In February 1998, the Company acquired control of Nanopierce Technologies, Inc.
in a transaction accounted for using the purchase method of accounting.  The
results of operations of Nanopierce have been included in the Company's
financial statements from the date of acquisition.  The unaudited results of
operations of the Company on a pro forma basis, as though Nanopierce has been
acquired as of October 1, 1997 are as follows for the six months ended March 31,
1998:

          Revenue                                    $       -
          Loss from continuing operations            $(2,958,000)
          Net Loss                                   $(5,962,000)
          Net Loss applicable to
            common shareholders                      $(6,093,000)
          Net Loss per share                         $     (0.20)


10.  SUBSIDIARY STOCK TRANSACTIONS

During the six months ending March 31, 1999, Nanopierce issued 75,000 shares of
Series B Preferred Stock at $10 per share, resulting in net proceeds of $660,000
(net of $90,000 of issuance costs).  As of March 31, 1999, all of the Series B
Preferred Stock were converted into common shares of Nanopierce.

During the three months ended March 31, 1999, Nanopierce issued 1,000,000 shares
of common stock for $200,000.


11.  STOCKHOLDERS EQUITY

In connection with the acquisition of M.C. Davis Co., Inc. (M.C. Davis) in 1996,
the Company guaranteed the former shareholders of M.C. Davis that the 277,778
shares of the Company's common stock issued to them would have a value on
October 8, 1998 of not less than $4.00 per share. On October 8, 1998, the price
per share of the Company's common stock was $.025.  In satisfaction of the
guarantee, in October 1998, the Company agreed to transfer 850,000 restricted
common shares of its Nanopierce common stock held by the Company and issue
1,293,899 restricted shares of the Company's common stock to certain former
shareholders.  As a result of these transactions, the Company recorded a loss of
$32,000 in fiscal year 1998.  On February 8, 1999 the Company agreed to issue
1,424,864 restricted shares of the Company's common stock to certain additional
former shareholders of M.C. Davis.  The Company recognized a loss of $85,000 in
the quarter ended December 31, 1998 in connection with the February 8, 1999
agreement.

12.  CONTINGENCIES

SUBSIDIARY SHAREHOLDER AGREEMENT

Subsequent to the Company's 1997 acquisition of Sigma, Sigma issued $1,700,000
of promissory notes in a private placement.  In connection with the Company's
decision to discontinue operations of Sigma in June 1998, the Company entered
into an agreement in September 1998 to place 750,000 shares of Nanopierce common
stock in escrow, to be held for the benefit of the Sigma investors.  The
agreement stipulates that the 750,000 shares may be sold in order to utilize the
proceeds


                                        9

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)
                         SIX MONTHS ENDED MARCH 31, 1999


to pay the Sigma investors.  The Agreement provides that no sale of shares may
be made below $2.00 per share and the volume of sales cannot exceed 20% of the
average weekly trading volume of the common stock of Nanopierce prior to the
date of the transaction.  Any shares not required to be sold are to be returned
to the Company.  The Company is not required to provide any further shares of
Nanopierce or any other consideration in the event the sale of these shares is
insufficient to repay all the obligations.

LICENSE AGREEMENTS

Nanopierce has license agreements with third parties which allow the third
parties to utilize defined aspects of the intellectual property rights in return
for royalty fees.  All but one license agreement is idle and therefore these
agreements have not produced any royalty fees for Nanopierce.  With regard to
all current licensees, Nanopierce is involved in pending litigation with a third
party who is asserting ownership of the rights to the related royalty revenues.
Royalties under this agreement through March 31, 1999 total approximately
$64,000.  These monies are being held in an escrow account, outside of
Nanopierce's control, until the litigation is resolved.  Although management
believes that Nanopierce will ultimately be successful in defending this matter,
the Company has not recognized any royalty revenue until the ultimate outcome
can be determined.  In the opinion of management, the ultimate disposition of
this matter will not have a material impact on the Company's operations or the
further development of the PI Technology.



































                                        10

<PAGE>



     ITEM 2.  MANAGEMENTS'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
                              RESULTS OF OPERATIONS

GENERAL

The following discussion should be read in conjunction with the attached
condensed consolidated financial statements and notes thereto, and with the
Company's audited consolidated financial statements and notes thereto for the
year ended September 30, 1998.   This report contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 31E of the Securities Exchange Act of 1934, as amended.  Actual results
could differ materially from those anticipated in forward-looking statements.

On February 26, 1998 Intercell Corporation transferred all of the intellectual
property of its wholly owned subsidiary Particle Interconnect Corporation to
Nanopierce Technologies, Inc for 7,250,000 shares of common stock of Nanopierce
and 100 Series A 8% Voting, Convertible, Cumulative, Participating, Preferred
shares of Nanopierce.  The preferred shares are convertible into 7,250,000
shares of common stock.  Intercell Corporation has an approximately 74%
controlling interest in Nanopierce Technologies, Inc, a public company, on a
fully diluted basis.

Intercell Corporation discontinued all operations of its majority owned
subsidiary Sigma 7 Corporation, a manufacturer of memory modules located in San
Diego, CA, on June 5, 1998.  Sigma 7 Corporation subsequently filed for
protection under Chapter 7 of the United States Bankruptcy Code on December 30,
1998.

The Company is currently engaged in the design, development and licensing of
products using its patented particle interconnect technology, through its
majority owned subsidiary Nanopierce Technologies, Inc.

In December 1997, the Company issued convertible debentures and attached
warrants for $1,500,000.  Of this total $674,000 has been repaid.

RESULTS OF OPERATIONS

REVENUES:

The Company had no revenue from continuing operations for the periods ended
March 31, 1999 and 1998.

RESEARCH AND DEVELOPMENT

The Company had no research and development expenses for the periods ended
March 31, 1999 and 1998.

GENERAL AND ADMINISTRATIVE

General and administrative expenses decreased by approximately 72% for the three
months and six months ended March 31, 1999 compared to the three months and six
months ended March 31, 1998.   Management of the Company has attempted to reduce
and control expenses by selling and/or abandoning certain of its operations.

OTHER INCOME/EXPENSE

The Company earned $1,000 and $116,000 in interest income on its cash and
short-term investments during the three months and six months ended March 31,
1998.  The Company had no interest income during the three months and six months
ended March 31, 1999 due to the reduction in its cash and short-term
investments.  Interest expense for the three months and six months ended March
31, 1999 represented interest due on the convertible debentures issued in
December of 1997.  Interest expense for the three months and six months ended
March 31, 1998 represented interest due on the convertible debentures issued in
December, 1997 and interest on other debt that was outstanding in 1998.

                                       11

<PAGE>



LIQUIDITY AND CAPITAL RESOURCES

The independent auditors' report on Intercell Corporation's consolidated
financial statements as of September 30, 1998, and for each of the years in the
two-year period ended September 30, 1998 includes a "going concern" paragraph
that describes substantial doubt about the Company's ability to continue as a
going concern.

The Company has taken several steps regarding future operations including the
following.  In February and April 1998, the Company sold its interest in
California Tube Laboratory, Inc. and A.C. Magnetics, Inc. to raise additional
capital for ongoing operations.  The Company received $1,500,000 in cash,
including $200,000 in escrow, and a  $500,000 note receivable for the sale of
California Tube Laboratory, Inc.  The Company received $700,000 in cash for the
sale of A.C. Magnetics, Inc. which it used to pay down its debt on the
convertible debenture.

The Company has also discontinued operations at Sigma 7 Corporation and Particle
Interconnect Corporation during 1998 and in December 1998 Sigma filed for
protection under the U.S. bankruptcy laws.  The intellectual property rights to
the Particle Interconnect technology have been transferred to Nanopierce
Technologies, Inc. resulting in an approximate 74% ownership of that company on
a diluted basis.   Intercell Corporation has reduced its costs to a bare
minimum and is currently seeking its own financing.

During the six months ended March 31, 1999 and 1998 the Company's cash and cash
equivalents from continuing operations decreased by $225,000.  This decrease
was due primarily to net cash used in continuing operations.

During the six months ended March 31, 1999 and 1998 the Company had no capital
expenditures.

The Company believes that if financing of Nanopierce Technologies, Inc. can be
completed, adequate funding is then available to support operations for the
next twelve months.  The Company also believes that sales of its Nanopierce
Technologies, Inc. products and technology licenses will provide sufficient
funds to meet the Company's capital requirements for the next two years.  This
assumption is based on the signing of Technology Cooperation Agreements with
both ORGA Kartensystemes, GmbH, and Meinen, Ziegel & Co., an agreement to form
a joint venture with Cirexx Corporation and an Application and Development
Agreement with Multitape, GmbH & Co during the Spring of 1999.

To the extent the Company's operations are not sufficient to fund the Company's
capital requirements, the Company may enter into a revolving loan agreement with
a financial institution, or attempt to raise additional capital through the sale
of additional capital stock or through the issuance of debt.  At the present
time the Company does not have a revolving loan agreement with any financial
institution nor can the Company provide assurances that it will be able to raise
funds through issuance of debt or equity in the Company.

The Company recognizes the need to ensure its operations will not be adversely
impacted by Year 2000 software failures.  Software failures due to processing
errors potentially arising from calculations using the Year 2000 date are known
risks.  The Company is addressing this risk to the availability and integrity of
financial systems and the reliability of the operational systems.  Management
believes the total cost of compliance and its effect on the Company's future
results of operations will be insignificant.









                                       12

<PAGE>


                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

Louis DiFrancesco, the inventor of  Nanopierce's technology filed a lawsuit on
March 10, 1998 with the Superior Court of California, County of Santa Clara,
Case No. CV772523, purportedly against the Company and other parties.  Mr.
DiFrancesco made numerous allegations purportedly against the Company, its
employees, directors and officers and other affiliated companies and licensees.
Pursuant to a stipulation among the parties, none of the defendants were
required to file responsive pleadings until Mr. DiFrancesco's Complaint was
amended or refiled.  On December 24, 1998, DiFrancesco finally filed a First
Amended and Supplemental Complaint against the Company, Nanopierce and Paul H.
Metzinger.  The Company filed responsive motions to dismiss or stay the claims
arguing among other grounds that Mr. DiFrancesco was merely "forum shopping" and
that the action was an attempt to retry the same matters which are the subject
of litigation pending in the District Court in and for the City and County of
Denver, Colorado and therefore should be dismissed or stayed by the court.  The
Court entered an order staying any further prosecution of the action in
California pending the outcome of the Colorado litigation.  The Company believes
that the California action is without merit and intends to vigorously defend
itself with respect to the matter alleged, if the lawsuit is further prosecuted.

The Company filed suit against Mr. Louis DiFrancesco on October 5, 1998, with
the District Court for the City and County of Denver, Colorado, to enjoin him
from certain specified actions against the Company and the licensees and to
confirm Nanopierce's ownership of its intellectual property rights.  On October
19, 1998, the District Court for the City and County of Denver, Colorado issued
a temporary restraining order prohibiting Mr. DiFrancesco from, among other
things, claiming any ownership of Nanopierce's patents and claiming any rights
to royalty payments under Nanopierce's licenses.  On November 5, 1998, the
District Court for the City and County of Denver, Colorado issued a preliminary
injunction prohibiting Mr. DiFrancesco from: (i) contacting any actual or
potential customer, licensee or investor of the Company or its related entities
using the name "Particle Interconnect Research & Development" or any other name
confusingly similar to the Company's trade name and trademark "Particle
Interconnect"; (ii) contacting any actual or potential customer, licensee or
investor of the Company or its related entities under the auspices that he
represents, works for, or its associated with the Company; and (iii) making any
statement to any actual or potential customer, licensee or investor of the
Company or its related entities which directly or by implication asserts that
(a) he owns all or any portion of the patents or patent applications which he
previously has assigned to the Company or (b) his consulting agreement with
Particle Interconnect Corporation has not expired.
On November 24, 1998, Mr. DiFrancesco filed an answer in the District Court for
the City and County of Denver, Colorado, generally denying the allegations
contained in the Company's complaint and asserting certain affirmative defenses.
He also filed a Third Party Complaint against the Company, Nanopierce and Paul
H. Metzinger.  The answer also asserts counterclaims against the Company,
Nanopierce and Paul H. Metzinger, individually, for breach of contract, fraud in
the inducement and legal malpractice and seeks rescission of the merger pursuant
to which Particle Interconnect Corporation and seeks rescission of the merger
pursuant to which Particle Interconnect Corporation (a subsidiary of Intercell)
acquired the Particle Interconnect Technology and certain declaratory relief.
The Company, Nanopierce and Mr. Metzinger filed answers denying all of the
allegations contained in the DiFrancesco Complaint.  In addition, they filed
motions requiring DiFrancesco's counterclaims to be more definite and certain in
their alleged claims against the Company, Nanopierce and Metzinger.  The
District Court ruled in favor of the motions and required DiFrancesco to submit
amended counterclaims.  DiFrancesco failed to timely file the amended
Counterclaims by February 19, 1999 when due.  DiFrancesco did eventually file
amended counterclaims on April 5, 1999.  The Company, Nanopierce and Metzinger
filed motions to strike or dismiss the amended counterclaims for lacking the
specificity required and because they were untimely filed.  The Court denied
this motion.  The Company, Nanopierce and Metzinger filed Answers generally
denying the allegations of the Third Party Complaint and the Counterclaims and,
in turn, asserting affirmative defenses and Counterclaims against DiFrancesco.
DiFrancesco has yet to answer the Counterclaims.  The Court has scheduled the
matter for trial setting.
                                       13
<PAGE>


On July 1, 1998, the Company was served a summons and complaint naming it, its
subsidiary, Sigma and others affiliated with the Company, by Classic Trading,
Inc., a California corporation, with the Superior Court of the State California,
Count of Orange, CV 796047 (the " Classic Trading Lawsuit").  Classic Trading,
Inc. alleges breach of contact and believes that it is owed $135,000.00.  The
Company has filed an answer denying the allegations.  The litigation has not
been further prosecuted since then.

                        ITEM 2.     CHANGES IN SECURITIES

The Company made the following unregistered sales of its securities from January
1, 1999 to March 31, 1999.
<TABLE>
<CAPTION>

DATE OF SALE  TITLE OF SECURITIES   SHARES       CONSIDERATION          PURCHASER
------------  -------------------  ---------  -------------------  --------------------
<S>           <C>                  <C>        <C>                  <C>
      2/8/99  Common Stock           712,432  Settlement           Jesse Salazar
      2/8/99  Common Stock           712,432  Settlement           Kon Wong
     2/18/99  Common Stock         1,024,073  Series C Conversion  Banque Edouard Swiss
      3/5/99  Common Stock           906,121  Series C Conversion  Banque Edouard Swiss
</TABLE>


                       EXEMPTION FROM REGISTRATION CLAIMED

All of the sales by the Company of its unregistered securities were made by the
Company in reliance upon Section 4(2) of the Act.  All of the individuals and/or
entities listed above that purchased the unregistered securities were all known
to the Company and its management, through pre-existing business relationships,
as long standing business associates, friends, and employees.  All purchasers
were provided access to all material information which they requested and all
information necessary to verify such information and were afforded access to
management of the Company in connection with their purchases.  All purchasers of
the unregistered securities acquired such securities for investment and not with
a view toward distribution, acknowledging such intent to the Company.  All
certificates or agreements representing such securities that were issued
contained restrictive legends, prohibiting further transfer of the certificates
or agreements representing such securities, without such securities either being
first registered or otherwise exempt from registration in any further resale or
disposition.

                              ITEM 6.     EXHIBITS
EXHIBITS
Exhibit 11     Statement of Computation of Earnings per Share
Exhibit 27     Financial Data Schedule



















                                       14

<PAGE>



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                    INTERCELL CORPORATION
                                    (REGISTRANT)

Date:     August 4, 1999              By: /s/  Paul H. Metzinger
                                      --------------------------
                                        Paul H. Metzinger, President,
                                        Chief Executive Officer &
                                        Chief Financial Officer


















































<PAGE>